Log in to your Inderes Free account to see all free content on this page.

Toleranzia

0.481

SEK

0 %

Less than 1K followers

TOL

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview

Ownership

Investor consensus

0%

+3.89%

+18.18%

-19.02%

-19.02%

-22.67%

-53.97%

-76.61%

-92.7%

Toleranzia is a research company. The company is active in the development of drug candidates for the treatment of autoimmune diseases. The company has developed a platform technology with a focus on the muscle disease myasthenia gravis. In addition, the technology has been used in other areas such as diabetes and multiple sclerosis. Research collaborations take place in collaboration with external partners within the work area. The headquarters are located in Gothenburg.

Market cap

130.33M SEK

Turnover

5.04M SEK

Revenue

EBIT %

P/E

Dividend yield-%

Financial calendar

29.8.

2025

Interim report Q2'25

11.11.

2025

Interim report Q3'25

All

Press releases

ShowingAll content types

Regulatory press release6/27/2025, 2:40 PM

Nasdaq Stockholm approves Toleranzia’s application for delisting

Regulatory press release6/25/2025, 4:10 PM

Toleranzia applies for delisting of the Company’s shares from Nasdaq First North Growth Market, conditional upon completion of the merger with Flerie

Regulatory press release6/5/2025, 10:20 AM

Announcement from the 2025 Annual General Meeting of Toleranzia AB (publ)

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account

Stock market's most popular morning newsletter

Analyst comments and recommendations

Stock comparison tool

PREMIUM account

All company reports and content

Premium tools (e.g. insider transactions & stock screener)

Model portfolio

Regulatory press release5/7/2025, 11:50 AM

Bulletin from extraordinary general meeting in Toleranzia AB

Regulatory press release5/6/2025, 5:40 AM

Notice of Annual General Meeting in Toleranzia AB (publ)

Regulatory press release5/6/2025, 5:30 AM

Toleranzia AB: Interim report first quarter 2025

Regulatory press release4/23/2025, 6:20 AM

Toleranzia AB: Annual report for the financial year 2024

Press release4/22/2025, 6:00 AM

Toleranzia brings forward publication of annual report

Regulatory press release4/10/2025, 7:05 AM

Toleranzia AB signs conditional loan agreement of SEK 20 million

Regulatory press release4/4/2025, 6:30 AM

Notice of Extraordinary General Meeting in Toleranzia AB

Press release3/28/2025, 6:32 AM

Toleranzia AB: BioStock: Merger strengthens Toleranzia's prospects

Regulatory press release3/25/2025, 9:32 AM

Statement by the Board of Directors of Toleranzia in view of the merger offer by Flerie

Regulatory press release3/25/2025, 9:30 AM

Flerie and Toleranzia have agreed on a merger plan to take Toleranzia private

Press release3/11/2025, 8:55 AM

Toleranzia seeks a scientific advice meeting with the Danish Medicines Agency

Regulatory press release2/21/2025, 8:33 AM

Toleranzia AB: Year-End Report 2024

Regulatory press release2/20/2025, 2:57 PM

Toleranzia’s clinical trial application (CTA) for TOL2 approved in Germany while declined in Denmark

Regulatory press release2/8/2025, 6:25 PM

Toleranzia’s clinical trial application (CTA) for TOL2 approved in Sweden

Press release1/23/2025, 4:35 PM

Toleranzia AB provides update on clinical trial application

Regulatory press release11/28/2024, 10:00 AM

Toleranzia AB appoints SKMG as new Certified Adviser

Regulatory press release11/25/2024, 6:30 AM

Toleranzia AB publishes the Nomination Committee

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.